Pre-Vetted Life Sciences AI Consulting Partners Only
Advisory comes first, then we connect you with vetted partners who know the science. You gain senior strategy plus a delivery team proven in regulated life sciences settings.
Life Sciences AI Consulting
AutoArmy’s life sciences AI consulting connects pharma, biotech, and medical device leaders with vetted experts, mapping a vendor-neutral path to faster discovery, cleaner trials, and compliant AI across the product lifecycle.
Services
The science is hard and the rules are strict. McKinsey estimates gen AI could create $60 billion to $110 billion a year for pharma and medical products. These six gaps slow life sciences AI consulting most, each with the evidence behind it.
Discovery takes years and billions. Rivals using AI screen targets in weeks, not months, compounding their lead. Slow, manual research cedes the best molecules to faster rivals. Speed is the whole game in discovery.
Trials drown teams in data. IBM finds only 29% of technology leaders say their data meets the standards AI needs. Messy trial data hides signals and slows decisions. Clean, connected data is the fix.
Regulators now scrutinize AI closely. Peer-reviewed research counts 132 AI/ML submissions to the FDA in 2021, a tenfold jump. Weak validation gets a filing sent back. That delay can cost a quarter or more. Good validation prevents it.
SaMD rules are unforgiving. Cisco finds only 31% of organizations say their talent is ready for AI. Few device teams hold deep AI compliance skills in-house. A matched partner brings them fast, without a long hire.
Safety data piles up after launch. Gartner finds 63% of organizations lack the data practices AI needs. Buried signals delay action on adverse events. Patients deserve faster, safer answers. AI surfaces the safety signal sooner, before it becomes a crisis.
The wrong vendor misreads the science. MIT finds AI bought from specialized vendors succeeds about 67% of the time, roughly double generic builds. Domain gaps cost time and credibility with regulators. The right specialist avoids that risk.
Services
Every engagement stays advisory. We assess your goals, scope what fits a regulated setting, and guide the work safely. You own each decision, and FDA-aware governance is built in from the start.
Map where AI moves the needle across R&D, trials, and commercial. Advisory work scores use cases by value, feasibility, and regulatory risk. It then sequences a roadmap tied to ROI. The plan targets speed to market.
Tame the data that slows trials. Advisory scoping covers protocol design, cohort selection, and data automation across trial systems. Studies then enroll faster and amend less. The evidence comes out cleaner for submission.
Build models regulators will accept. We align validation, documentation, and oversight to FDA expectations and the NIST AI RMF. Submissions and SaMD then hold up under review, not get returned.
Catch safety signals sooner. Advisory design applies machine learning to adverse event and real-world data, so pharmacovigilance teams spot trends earlier and protect patients across the postmarket lifecycle.
Turn genomic data into discovery. Scoping covers the pipelines and models that analyze genomic and multi-omic data. Biotech teams then find targets and biomarkers faster. The compute and governance are built to scale.
Protect quality and supply. Advisory work maps AI for manufacturing quality control and supply chain forecasting. Production then holds standards. Therapies reach patients on time. Shortages and recalls drop. Patients get their therapies on schedule. Trust holds.
Next step
Get an independent read on your highest-value, FDA-aware AI opportunities, plus a roadmap your team can act on. No long commitment, just a clear next step.
Use cases
These use cases deliver measurable value across the lifecycle. Each pairs a real workflow with the result it produces.
Foundation models screen molecular targets in weeks, not months. Research teams then pursue the best candidates faster. Less effort goes to dead ends. The pipeline fills with stronger candidates. Bets get smarter, and budgets stretch further.
AI designs trial protocols and selects cohorts from real-world data. Studies enroll the right patients faster. Costly amendments and delays drop. Trials reach readouts sooner. Time saved is money saved, and patients wait less for new therapies.
Models check submission packages against regulatory expectations and flag validation gaps early. Regulatory teams then file with fewer rejections. Rework drops sharply. Reviews go more smoothly. Approvals come faster, and products reach market sooner.
AI scans real-world and postmarket data for safety signals. Adverse events surface earlier. Teams act fast, and patients stay protected after launch.
Gen AI drafts study reports and regulatory documents from source data. Medical writers move faster. Humans still review every claim before it goes out.
AI inspects output and forecasts demand across the supply chain. Manufacturing holds quality and avoids the shortages that delay therapies and erode trust.
Why AutoArmy
Our model is simple. Independent advice comes first, and a connection to the right delivery team follows. You get strategy and execution without the usual handoff gap.
Advisory comes first, then we connect you with vetted partners who know the science. You gain senior strategy plus a delivery team proven in regulated life sciences settings.
Partners are matched to pharma, biotech, or medical device, not a generic bucket. That fit means the team already knows your regulators, data, and product lifecycle. Less ramp-up, more progress.
Partners bring real experience with FDA validation and SaMD rules. Your AI is built to pass review. A rejection that costs months is the risk we help you avoid.
Skip the long RFP cycle. Because the network is vetted in advance, the right team starts in days, so your pipeline keeps moving instead of waiting on procurement.
Every partner meets the privacy and security bar life sciences demands. Controls map to HIPAA, GDPR, and SOC 2, so patient and trial data stay protected.
No generalist overhead or junior ramp-up. You work with people who know the science and the rules. The engagement moves fast, and the advice lands right.
Next step
Tell us your pipeline and your goals. We will map the path and match you with a vetted, regulated-ready team. The first step is a short assessment.
FAQ
Straight answers to the questions pharma and biotech leaders ask most.
It is advisory help that applies AI across the life sciences lifecycle: discovery, clinical trials, regulatory, safety, and manufacturing. Advisors assess your goals and compliance needs, prioritize use cases, and match you with a delivery team that knows the science. The aim is measurable value, like faster discovery and cleaner submissions, all under FDA-aware governance, not an experiment that stalls.
Widely, and growing fast. Teams use machine learning to identify drug targets, design trials, select patient cohorts, draft regulatory documents, and detect safety signals in real-world data. Generative AI now speeds medical writing and discovery. McKinsey estimates gen AI could add $60 billion to $110 billion a year to pharma and medical products, much of it from R&D and operations productivity.
Domain depth first: real experience with FDA validation, SaMD rules, and trial data, not generic AI skills. Look for proof in your sub-vertical, strong data privacy and security, and a track record of getting models through review. Favor advisors who stay vendor-neutral, so the recommendation fits your science and pipeline rather than a single platform.
We begin with an advisory assessment of your goals, data, and compliance needs. From there we match you with vetted partners whose record fits your sub-vertical and regulators. Because we stay vendor-neutral, the recommendation follows your needs, not a quota. You keep one accountable advisor, gain a proven team, and approve the partner before any work begins.
Faster than a traditional RFP. A focused assessment can begin within days, since the partner network is vetted in advance. An initial use case, like documentation AI or a discovery pilot, can show value in weeks. Advisors sequence the work so early wins are proven, and compliance is validated before scaling.
At minimum, FDA expectations for AI used in drug submissions and Software as a Medical Device, plus HIPAA for protected health information and GDPR for global trials. Strong partners also map to the NIST AI RMF and SOC 2 for security. Advisors confirm a partner’s regulatory experience before any introduction, so your AI is built to pass review.
Make the right first conversation
Businesses see real AI returns by making fewer wrong decisions early. AutoArmy’s advisory process helps businesses make the right call before the budget is set.